复发性或转移性宫颈癌患者的治疗偏好：美国的一项离散选择实验
Treatment preferences of patients with recurrent or metastatic cervical cancer: a discrete choice experiment in the US.
作者信息
Thaker Premal H, Lu Hui, Zhang Yitong J, Trapali Myrto, Swinburn Paul, Krucien Nicolas, White Doris, Chaiprasert-Paguio Joslyn, Pothuri Bhavana, Ting Jie
机构信息
Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO, USA.
Evidera, London, UK.
出版信息
Gynecol Oncol Rep. 2025 Sep 13;61:101947. doi: 10.1016/j.gore.2025.101947. eCollection 2025 Oct.
OBJECTIVE
This study assessed treatment preferences of patients with recurrent/metastatic cervical cancer, a disease with poor prognosis.
METHODS
A survey with two discrete choice experiments was completed by 150 patients with recurrent/metastatic cervical cancer in the US. Discrete choice experiment 1 included treatment attributes, and discrete choice experiment 2 included risk mitigation plan attributes.
RESULTS
Participants valued 12-month overall survival rate as the most important attribute, followed by disease control rate; both efficacy attributes were rated as more important than the risk of side effects such as peripheral neuropathy and corneal side effects. Participants' willingness to accept a treatment profile requiring a risk mitigation plan was influenced by the number of clinic visits and out-of-pocket costs.
CONCLUSIONS
Patients with recurrent/metastatic cervical cancer prioritize overall survival and disease control rate as the most important attributes. These findings can be used to inform shared decision-making and treatment discussions among patients, clinicians, and the care team.
目的
本研究评估了复发性/转移性宫颈癌患者的治疗偏好，这是一种预后较差的疾病。
方法
美国150例复发性/转移性宫颈癌患者完成了一项包含两个离散选择实验的调查。离散选择实验1涵盖治疗属性，离散选择实验2涵盖风险缓解计划属性。
结果
参与者将12个月总生存率视为最重要的属性，其次是疾病控制率；这两个疗效属性的评级均高于周围神经病变和角膜副作用等副作用风险。参与者接受需要风险缓解计划的治疗方案的意愿受门诊就诊次数和自付费用的影响。
结论
复发性/转移性宫颈癌患者将总生存率和疾病控制率列为最重要的属性。这些发现可用于为患者、临床医生和护理团队之间的共同决策和治疗讨论提供参考。
Zotero 插件